Global Skeletal Dysplasia Market Size Study & Forecast, by Type (X-linked hypophosphatemia, Hypophosphatasia, Achondroplasia, Fibrodysplasia ossificans progressive, Multiple osteochondromas, Others), by Treatment (Medication, Surgery, Others) and Regional

Global Skeletal Dysplasia Market Size Study & Forecast, by Type (X-linked hypophosphatemia, Hypophosphatasia, Achondroplasia, Fibrodysplasia ossificans progressive, Multiple osteochondromas, Others), by Treatment (Medication, Surgery, Others) and Regional Analysis, 2022-2029

Global Skeletal Dysplasia Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Skeletal dysplasia is a rare disease which manifests itself in over 450 different forms. It's usually considered osteochondrodysplasias. It has an impact on bone and cartilage growth and development. This condition can be so severe that it results in abnormal adult development or the death of newborns. Skeletal dysplasia is a rare condition that is challenging to diagnose. Slow growth, deformities such as a huge head, short upper arms or legs, twisted bones, arthritis, or joint pain are a few of the signs. The condition has a severe impact on infants, and early detection raises awareness. Defective genes, which may be inherited from ancestors or altered while a child is developing, cause this disorder. Identifying the mutant gene is another problem. Therefore, major companies are investing significantly in the research and development of treatments for this inherited disorder. The key factors such as rising prevalence of skeletal dysplasia, commercialization of novel drugs and presence of pipeline products and growing government expenditure on healthcare sector are anticipated to support the market growth during forecast period.

Moreover, the significant raise in prevalence of skeletal dysplasia and raise in adoption of skeletal dysplasia therapies is anticipated to create the lucrative demand for the market during forecast period. For instance, the prevalence of skeletal dysplasia is predicted to be 2.4 per 100,000 newborns worldwide every day, according to a journal that was published on UpToDate. According to ultrasound screening, there are 7.5 cases of skeletal dysplasia per 100,000 pregnant women. Additionally, rising number of clinical trials and collaborative research for skeletal dysplasia treatment is anticipated to create lucrative opportunities for the market. However, the strict regulatory rules and high-cost stifle market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Skeletal Dysplasia Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the substantial presence of major pharmaceutical and biopharmaceutical companies, presence of well-established healthcare infrastructure, high purchasing power, and rise in the adoption rate of skeletal dysplasia in the region. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as rise in pediatric population and increase in prevalence of skeletal dysplasia including achondroplasia, thanatophoric dysplasia, osteogenesis imperfecta, hypochondroplasia and others would create lucrative growth prospects for the Skeletal Dysplasia market across Asia Pacific region.

Major market players included in this report are:
Amgen Inc.
AstraZeneca plc
Cipla Ltd
Merck KGaA
Ascendis pharma a/s
F. Hoffmann-La Roche AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
Biomarin Pharmaceuticals Inc.

Recent Developments in the Market:
Nov. 2022, The U.S. Food and Drug Administration (FDA) granted VOXZOGO (vosoritide) for Injection accelerated approval, according to BioMarin Pharmaceutical Inc. It is intended to accelerate linear growth in children with achondroplasia who are five years old and older and have open epiphyses (growth plates).

Global Skeletal Dysplasia Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Treatment, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
X-linked hypophosphatemia
Hypophosphatasia
Achondroplasia
Fibrodysplasia ossificans progressive
Multiple osteochondromas
Others

By Treatment:
Medication
Surgery
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Amgen Inc.
AstraZeneca plc
Cipla Ltd
Merck KGaA
Ascendis pharma a/s
F. Hoffmann-La Roche AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
Biomarin Pharmaceuticals Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.